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ABSTRACT 
The current level of morbidity and mortality among dogs due to canine distemper virus infection raise concerns about the 
effectiveness of commercially available DHLPPi vaccines. The prevalence of the disease despite vaccination warranted the 
evaluation of the potency of vaccines that are used for routine vaccination in Nigeria. This study was conducted to investigate 
antibody responses to the three common brands of DHLPPi vaccines for dogs and to recommend the best immunogenic brand 
for routine vaccination in dogs in Nigeria. Twenty local breed of dogs, age 8 -14 weeks were purchased from dog breeders in 
Ibadan, Oyo-State, Nigeria. The dogs were screened for heamoparasites and endoparasites. Those that were positive were treated 
appropriately and they were acclimatized for three weeks in the University of Ibadan Veterinary Teaching Hospital kernels. They 
were divided into four groups tagged A, B, C and D. They were fed with rice and meat and formulated rations and served fresh 
clean water ad-libitum. Groups A, B and C were vaccinated while Group D was not vaccinated and served as the control. Blood 
samples were collected before vaccination (day 0) and weekly for four weeks and 90 days post-vaccination. The sera of collected 
blood samples were subjected to ELISA test. Mean values of ELISA antibody titers were calculated and the mean values obtained 
were compared for significant differences using ANOVA test and student t-test. The antibody titres of the three groups A, B and 
C were observed to increase within a week of vaccination, and the three vaccinated groups showed variable antibody responses 
on different days of samplings.characterised with rising and waning of antibodies. Group D was observed to be low titres of 
antibody throughout the study period. From these findings, all the vaccines were potent, however, comparatively vaccine C was 
the best, vaccine B was better than A. Vaccine C is therefore strongly recommended for use in dogs for routine vaccination and 
a booster dose should be administered 4-5 weeks after first dose for optimum humoral immunity against canine distemper virus 
infection. Seromonitoring is essential in planning vaccination regimen for dogs. Other factors that can affect the effectiveness of 
vaccine during storage, transportation and administration should be considered for a desirable result 
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INTRODUCTION 
 
Canine distemper, (sometimes termed hardpad disease in 
canine), is a highly contagious viral disease that affects a wide 
variety of animal families, including domestic and wild 
species of dogs, coyotes, foxes, pandas, wolves, ferrets, 
skunks, raccoons, and large cats, as well as pinnipeds, some 
primates, and a variety of other species (Ikeda et al., 2001). 
The canine distemper virus (CDV) is a member of the genus 
Morbillivirus, of the family Paramyxoviridae, and order 
Mononegavirales (Ikeda et al., 2001). CDV is related 
antigenically to dolphin distemper virus (DDV), human 
measles virus (HMV), peste de petits ruminant virus (PPRV) 
and rinderpest virus (RPV) (Eghafona et al., 2007) 
 In dogs, canine distemper affects several body systems 
(i.e. it is a multi-systemic disease) (Kapil et al., 2008) 
especially the gastrointestinal and respiratory tracts and 
central nervous system. The common symptoms include high 
diphasic fever, conjunctivitis, oculo-nasal discharge, labored 
breathing and coughing, vomiting and diarrhea, loss of 
appetite, lethargy, and hardening of nose and footpads 
(hyperkeratosis) (Kapil et al., 2008). 
 
www.ajbrui.org 
Antibody Response to Canine Distemper Virus Vaccine  
 Afr. J. Biomed. Res. Vol. 22, No.3 (September) 2019 Adejumobi et al 334 
 Morbilliviruses cause an acute disease characterized by 
generalized immunosuppression, rash, respiratory and 
gastrointestinal signs, and occasional but devastating 
neurological complications (Schneider & Schneider, 2008). 
The advent of preventive vaccination programmes has gone a 
long way to reduce the incidence of the disease in recent years 
(McCaw et al., 1998).  
 Histopathologically, canine distemper is reported to be 
characterized by cellular infiltration of the central nervous 
system, diffuse encephalitis of the forebrain, perineuronal and 
perivascular degeneration in the brain, presence of inclusion 
bodies in different cell types and interstitial 
bronchopneumonia (Tipold et al., 1999, Ezeibe, 2005). There 
is also presence of hyperaemia and depopulation of splenic 
corpuscles, hyperaemia and degeneration of renal tubular 
epithelia and hyperkeratosis of skin (Ezeibe, 2005). 
 Horst (1975) reported that the most effective method of 
controlling canine distemper is mass vaccination of dogs and 
other carnivores. Most commercial canine distemper vaccines 
are made from the Onderstepoort strain of the virus isolated in 
South Africa (Yoshida et al., 1999). However, strains different 
from the Onderstepoort strain have also been isolated 
(Iwatsuki et al., 2000). Although vaccination against CDV 
with attenuated virus can protect the majority of animals, this 
protection does not necessarily extend to the field strains 
(Wang et al., 2011). 
 In Nigeria, commercially available CDV vaccines are 
marketed and administered in combination with hepatitis, 
leptospirosis, parvovirus and parainfluenza vaccines 
(DHLP+Pi combined vaccine) (Greene and Appel, 2006). It is 
recommended that puppies be given a series of vaccinations to 
stimulate active immunity as maternally derived immunity 
declines. This should then be followed by annual 
revaccination to maintain immunity (Greene, 1990).  
 However, the usefulness of annual revaccination of dogs 
is still widely debated. Smith (1995) has suggested that a more 
cost-effective and beneficial approach is to first measure 
serum antibody titres to determine the necessity of 
revaccination. 
 
MATERIALS AND METHODS 
 
Study Population: Twenty local dogs, age between 8 and 14 
weeks were purchased from dog breeders in Ibadan, Oyo-
State, Nigeria. They were fed for five weeks in the dog kennel 
of the Veterinary Teaching Hospital, University of Ibadan and 
were acclimatized for the period. During the period of 
acclimatization, the dogs were screened for heamoparasites 
and endoparasites, the infected ones were treated 
appropriately and they were separated into four groups of 5 
dogs per group, tagged A, B, C and D in separate kennel units. 
The dogs were fed with cooked rice, beans, meat and 
formulated diet containing indomie waste, fish meal, maize 
and soya meal. Clean water was given ad-libitum and 12 hours 
of daylight and darkness were maintained through the period 
of the experiment.   
 Blood samples were collected before the dogs were 
vaccinated (day 0). Vaccines labelled A, B and C were 
administered to the respective groups A, B and C while group 
D (control) was not vaccinated. After vaccination, blood 
samples were collected weekly for four weeks and lastly on 
day 90. All the animals received humane care according to the 
criteria outlined in the Public Health Service Policy on 
Humane Care and the Use of Laboratory Animals (P.H.S., 
1996). 
Sample Collection and serum preparation 
Dogs in each groups were bled via jugular venipuncture using 
21-guage needles and 10 ml syringes. Four milliliters (4ml) of 
blood were collected into plain bottles for serum. The bottles 
were left slanted on the bench at room temperature for the 
blood to clot. 
Blood samples collected into plain bottles were spun in 
centrifuge at 5000 rpm for 15 minutes and serum samples were 
harvested into new plain sample bottles, then stored at -20°C 
till all samples were collected. The serum samples per group 
were subjected to CDV indirect antibody  
 
ELISA: An Indirect ELISA test was carried out on the sera 
using the ELISA antibody test kit for Canine distemper 
manufactured by INGENASA, C/Hnos, Garcia Noblejas, 39 
28037 – MADRID, SPAIN. The recommended protocol by 
the manufacturer was followed. 
 
Calculations and interpretation of results 
The serum CDV antibody titre was calculated as described in 
the ELISA kit manufacturer’s protocol (INGENASA, C/Hnos, 
Garcia Noblejas, 39 28037 – MADRID, SPAIN) 
The cut off optical density (O.D) was calculated by 
multiplying the O.D of positive control by 0.2 and calculating 
the mean of the two wells. 
Every samples with O.D lower than the cut off are regarded as 
negative while those with O.D higher than the cut off are 
regarded as positive. 
The positive samples were categorized into three as follows: 
▪ Low titres (corresponding to IFI values of 1/20-1/40). 
These samples show O.D between 0.2 × O.D of positive 
control and 0.4 × O.D of positive control. 
▪ Medium titres (corresponding to IFI values of 1/80-1/160). 
These samples show O.D between 0.4 × O.D of positive 
control and 0.8 × O.D of positive control. 
▪ High titres (corresponding to IFI values of ≥ 1/320). These 




Mean values of ELISA antibody titers were calculated and the 
mean values obtained were compared for significant 





As shown in Fig. 1, the mean CDV antibody titers were 
interpreted using the model provided by the ELISA kit 
manufacturers as follows:  
Titre value of positive control = 0.094 while Titre value of 
negative control = 0.0014. (Low titres = Titres between 0.019 
– 0.037; Medium titres = Titres between 0.037 – 0.075 while 
High titres = Titres greater than 0.075). 
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Figure 1.  
Line graph showing Canine distemper vaccinal antibody titers in 
Nigerian local dogs on three types of vaccines. 
 
Dogs in groups A, B, C and D had low titres of antibody 
before the vaccination as shown in the respective serum 
antibody titres of 0.036±0.010, 0.029±0.008, 0.034±0.018 and 
0.036±0.010 on day 0. There was no significant difference in 
the mean titre values among the groups of dogs used in this 
study (Figure 2). 
 
Figure 2.  
Graph showing the mean ± standard deviation (SD) serum antibody 
titers to CDV in dogs sampled on day 0 prior to vaccination. 
Significance at P<0.05.  
 
 
Figure 3:  
Graph showing the mean ± standard deviation (SD) serum antibody 
titers to CDV in dogs on day 7 following a single dose of three types 
of DHLPPi vaccines. Significance at P<0.05 and ‘d’ indicates 
significance when titres of other groups are compared to group D. 
Group A, Band C received vaccines tagged A,B and C respectively 
while Group D was the control. 
 
On day 7, the mean antibody titres were 0.068±0.012, 
0.075±0.010, 0.086±0.012 and 0.036±0.001 respectively for 
groups A, B, C, and D. In comparison to the mean titre of 
group D, a significant (P<0.05) increase was observed in 
groups A, B, C. The antibody titre of group A was observed 
to be within medium titre range, those of groups B and C were 
within high titre range while that of group D was within low 
titre range (Figure 3)  
On day 14, the mean antibody titres for groups A, B, C and 
D were 0.081±0.015, 0.083±0.013, 0.094±0.017 and 
0.038±0.007 respectively. The antibody titres of group A, B 
and C was observed to be within high titre category while that 
of group D was of low titre category. A significant (P<0.05) 
increase was observed in the titres of groups A, B, and C when 
compared to group D (Figure 4).   
 
Figure 4:  
Graph showing the mean ± standard deviation (SD) serum antibody 
titers to CDV in dogs on day 14 following a single dose of three types 
of DHLPPi vaccines. Significance at P<0.05 and ‘d’ indicates 
significance when titre of other groups are compared to group D. 
Group A, Band C received vaccines tagged A,B and C respectively 
while Group D was the control. 
 
 
Figure 5:  
Graph showing the mean ± standard deviation (SD) serum antibody 
titers to CDV in dogs on day 21 following a single dose of three types 
of DHLPPi vaccines. Significance at P<0.05 and ‘d’ indicates 
significance when titres of other groups are compared to group D. 
Group A, B and C received vaccines tagged A, B and C respectively 
while Group D was the control. 
 
On day 21, the mean antibody titres for groups A, B, C and 
D were 0.080±0.013, 0.097±0.019, 0.100±0.010 and 
0.034±0.012 respectively. The antibody titre of group A, B 
and C were observed to be of high titre category while that of 
group D was of low titre category.  A significant (P<0.05) 
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increase was observed in the titres of groups A, B, and C when 
compared to group D (Figure 5). 
On day 28, the mean antibody titres for groups A, B, C and 
D were 0.079±0.011, 0.113±0.011, 0.099±0.018 and 
0.029±0.005 respectively. The antibody titres of group A, B 
and C were observed to be of high titre values while that of 
group D was of low titre value. A significant (P<0.05) increase 
was observed in the titers of groups A, B, and C when 
compared to group D. The antibody titre of group B was 
significantly (P<0.05) higher than that of group A (Figure 6).  
On day 90, the mean antibody titres for groups A, B, C and 
D were 0.071±0.005, 0.078±0.006, 0.084±0.007 and 
0.025±0.003 respectively. The antibody titre of group A was 
observed to be of medium titre, those of groups B and C were 
of high titres while that of group D could be categorized as 
low titre. A significant (P<0.05) increase was observed in the 
titers of groups A, B, and C when compared to group D. The 
antibody titre of group C was significantly (P<0.05) higher 
than that of group A (Figure 7).  
 
Figure 6:   
Graph showing the mean ± standard deviation (SD) serum antibody 
titers to CDV in dogs on day 21 following a single dose of three types 
of DHLPPi vaccines. Significance at P<0.05 and ‘d’ indicates 
significance when titres of other groups are compared to group D. 
Group A, B and C received vaccines tagged A, B and C respectively 
while Group D was the control. 
 
 
Figure 7:  
Graph showing the mean ± standard deviation (SD) serum antibody 
titers to CDV in dogs on day 21 following a single dose of three 
types of DHLPPi vaccines. Significance at P<0.05 and ‘d’ indicates 
significance when titres of other groups are compared to group D. 
Group A, B and C received vaccines tagged A, B and C respectively 
while Group D was the control. 
DISCUSSION 
 
This study was carried out to quantify and compare serum 
CDV antibodies responses to three different types of DHLPPi 
vaccine used in the vaccination of dogs in Nigerian local dogs 
(Canis lupus familiaris) using enzyme-linked immunosorbent 
assay (ELISA). This is to evaluate the efficacy of different 
brands of the imported DHLPPi vaccines used for routine 
vaccination of dogs and to determine the level of antibody 
protection within the period of our study.  
ELISA is an antibody detection and quantification 
technique that has been used for seropositivity test in a study 
carried out by Waner et al. (1998). Gill et al. (2004) also 
described ELISA as a highly sensitive test for CDV-specific 
antibodies independent of biological function. 
The purpose of vaccination is to protect animals from 
infectious diseases by enhancing a specific immune response 
(Taguchi et al., 2011). This immune response takes advantage 
of memory B cells produced as a result of a primary exposure 
to an antigen in order to produce a secondary immune 
response following a second exposure to the same antigen. 
The antibody responses to vaccination of the experimental 
dogs with a single dose of three different types of DHLPPi 
vaccine suggest significant increase in the antibody titres 
across all groups when compared with the control group. This 
observation agrees with a similar study by Durrani et al. 
(2012) on Mono- and polyvalent rabies vaccines in Dogs.  
The antibody titres post-vaccination in the three groups of 
dogs showed that the dogs produced CDV specific antibodies 
to the respective vaccine administered. There were significant 
differences in the antibody titre of the dogs in the three groups 
A, B, and C compared to the control group from day 7 through 
the entire period of the study. This agrees with the study of 
Wilson et al. (2017) who found antibody production in 
animals after vaccination and Gill et al. (2004) who reported 
antibody response from day 4 to a multivalent vaccine 
containing CDV. 
The trend of antibody titres in Groups A, B, and C showed 
differences in the duration of attaining peak antibody level 
based on the administered vaccines and declining. A booster 
dose will therefore be necessary to enhance the antibody 
production through secondary immune response. The timing 
of a booster dose of vaccine should however be based on 
serologic titre check (Wellborn et al., 2011). The mean 
antibody titre in group A dogs reached its peak on day 14 
through 21 and began to decline thereafter, Group B on the 
other hand had a steady rise in antibody titre till day 28 and 
subsequently declined. Group C also reached its peak on day 
21 and maintained it to day 28 but subsequently declined. 
Group D antibody titre was low through throughout the period 
of this study. From this trend of antibody titre, it can be 
inferred that a booster dose could safely be given to group A 
dogs at 4 weeks while groups B and C could be revaccinated 
from 5-6 weeks after the primary vaccination. This findings is 
different from the vaccination regimen recommended by Gill 
et al. (2004). They recommended revaccination on day 21 for 
a long lasting immunity based on their finding that the 
antibody titre reached its peak on day 12 but declined 
thereafter. 
We also found from this study that the titres of the four 
groups of dogs were low on day 0 but by day 7, the antibody 
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titres in Groups A and B had increased to medium titre while 
that of Groups C was high titre. The three groups had high 
titres till day 90 except the group A that had the titre reduced 
to medium status. This finding showed that the dogs had 
adequate protective antibody to day 90. This findings agreed 
with the report of Gill et al. (2004) who said that the 
serological responses in vaccinated animals correlate 
reasonably with protective immunity for CDV. The further 
said that continuous detection of high titre antibody and 
resistance to infection on field challenge with specific antigen 
are indicators of protection from CDV infection. 
  Persistent levels of morbidity or mortality due to CDV 
infection despite vaccination could be as a result of vaccine 
failure which ensues mostly from interference with maternally 
derived antibody and break in cold chain of vaccine 
administered as reported by Waner et al (1998). Failure of 
vaccination as a result of the presence of maternally-derived 
antibody in puppies up to 16 weeks of age has been widely 
documented. It is the result of maternally-derived antibody 
titre falling below protective levels but high enough levels to 
block an active immune response by the vaccinated puppies 
(Dongoyaro, 2010) 
The persistence of CDV may also be caused by infection 
due to challenge from local field strains of the virus (i.e. virus 
strains different from the ones used in producing the vaccine). 
Puppies with poor MDA may be vulnerable (and capable 
of responding to vaccination) at an earlier age, while others 
may possess MDA at such high titers that they are incapable 
of responding to vaccination until 12 weeks of age (Friedrich 
& Truyen, 2000). Vaccination regimen commonly practiced 
in Nigeria involving revaccination of the animals twice on 
monthly interval, this agrees with the recommendation of Paul 
et al. (2006) that dogs can be revaccinated twice after primary 
exposure. This practice will assist in reducing vaccine failure 
caused by MDA especially in places where there are no 
facilities for seromonitoring. 
Other factors like poor knowledge and attitude of dog 
owners towards vaccination and care of dogs, improper 
handling of vaccines and errors in administration may cause 
vaccine failure and may contribute to the prevalence of the 
disease despite availability of potent vaccines. 
Public education through mass media and public 
enlightenment campaign, use of posters, seminars at religious 
centers and children education about animal diseases and 
prevention measures are recommended by Adejumobi et al. 
(2016) as means of increasing people’s knowledge about 
diseases and steps to control vaccine preventable diseases of 
dogs.  
In conclusion, this study showed that the three vaccines 
used in this study are immunogenic. However vaccine C 
ranked best, followed by vaccine B while vaccine A gave the 
least response. Vaccines C and B are therefore potent and can 
safely be used for routine vaccination in Nigeria. Furthermore, 
a period of 4-5 weeks interval seems optimum for 
administration of booster dose of vaccine as shown by the 
result from this study.  
 To effectively ensure effectiveness of vaccination and 
efficient control of CDV in Nigeria, we recommend public 
education on the importance of animal immunization and mass 
vaccination. In addition, those factors that can cause vaccine 
failure should be put into consideration and avoided. 
Veterinarians should therefore handle vaccine properly, 
vaccines should be kept from sunlight and stored properly at 
recommended temperature. Vaccines should be reconstituted 
with recommended solvent and with appropriate volume and 
reconstituted vaccine should be used within the specified time 
and at the right dosage. Appropriate vaccination regimen 
should be followed, also primary and secondary vaccination 
should be done at the stipulated time intervals. On the other 
hand, animal that are sick, immunosuppressed, stressed or on 
steroid medication should not be vaccinated to ensure 
optimum immune response. Dog owners should be educated 
on disease control, biosecurity and vaccination. Dogs should 
be properly fed because vitamin and protein deficiency result 
in suppression of immune system. Dogs should be housed in 
a well-ventilated and hygienic kennel to get a good immune 
response to vaccination.  
 We also recommend that further study be carried out on 
the antibody response to secondary exposure of these vaccines. 
Also seromonitoring for adult dogs and pre-vaccination titre 
check for puppies should be done routinely to design 
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